Newsroom
February 1, 2023
The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, was the lead site for a study evaluating Phase I and Phase III clinical trials for elacestrant, a treatment for postmenopausal women and adult men with ER+/HER2- advanced or metastatic breast cancer. The U.S. Food and Drug Administration on Jan. 27 announced it approved the […]
December 20, 2022
The Mays Cancer Center at UT Health San Antonio — South Texas’ only National Cancer Institute-Designated Cancer Center — is putting a decades-old antidepressant drug to new use treating breast cancers that don’t respond to existing therapies. Research in the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio provided […]
December 13, 2022
Cancer survivors, cancer patients, friends, family and caregivers are invited to attend Living Beyond Cancer A-Z, a free symposium on Jan. 21, put on by the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. It will feature a full day of learning, empowerment and discovery and will take place […]
November 30, 2022
Elacestrant may improve care of metastatic ER+/HER2- tumors Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Nov. 30, 2022) — Phase III results of EMERALD, a clinical trial evaluating a novel oral drug therapy for metastatic ER-positive/HER2-negative (ER+/HER2-) breast cancer, will be presented Thursday, Dec. 8, at the San Antonio Breast Cancer Symposium (SABCS). Virginia Kaklamani, MD, […]
February 17, 2022
Contact: Will Sansom, (210) 567-2579, sansom@uthscsa.edu SAN ANTONIO (Feb. 17, 2022) — The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is receiving $10.9 million in new research and faculty recruitment awards announced Feb. 16 by the Cancer Prevention and Research Institute of Texas (CPRIT). The statewide cancer agency has […]
